Prof. Zhiwei Chen Attends First Close and Investment Ceremony of the HKU Entrepreneurship Engine Fund × Gobi Partners Joint Fund. 

Professor Chen has been invited to attend HKU Innovation Week 2025. HKU Innovation Week 2025 is the University of Hong Kong's annual celebration dedicated to showcasing innovation and entrepreneurship. The event highlights the societal contributions and achievements of students, staff, and alumni, aiming to inspire the HKU community especially the younger members to foster positive change and create a meaningful global impact. 

Our team’s innovations achieved notable recognition at the 51st International Exhibition of Inventions in Geneva.   We are proud to announce that our team was awarded the Gold Medal for our innovative invention at the 51st International Exhibition of Inventions in Geneva. This esteemed recognition reflects our commitment to excellence and our dedication to advancing technological progress.      Gold Medal Invention:   Sialic Acid-Anchored Neutralizing Antibody Against Diverse Pathogenic Influenza Viruses         The researchers at the University of Hong Kong's LKS Faculty of Medicine have developed a novel bispecific broadly neutralizing antibody called M‑SiaB. This antibody offers strong protection against both seasonal influenza and highly pathogenic avian influenza (HPAI) H5N1 in preclinical models. By targeting both the influenza virus and its receptor on human cells simultaneously, M‑SiaB addresses some limitations of current antibody therapies and presents a promising approach for pandemic influenza prevention and control.     Principle Investigators: Prof. Zhiwei CHEN, Chair Professor of Immunology & Immunotherapy; Suen Chi-Sun Professor in Clinical Science; Department of Microbiology, School of Clinical Medicine; Director of AIDS Institute, LKS Faculty of Medicine, HKU Prof. Runhong ZHOU, Assistant Professor, Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine, HKU  

Our team joined 5-a-side Soccer on 8 March 2026 (Sunday) and successfully advanced to the semi-finals. Congrat to the team on making the semi-final!!!!

香港大學微生物學系愛滋病研究所周潤宏助理教授獲國家科技重大專項資助 參與承擔愛滋病功能性治癒臨床研究   2026年1月11日上午，香港大學醫學院微生物學系/愛滋病所周潤宏助理教授作為課題「ICVAX聯合潛伏庫激活劑功能性治癒愛滋病的臨床研究」負責人參與由深圳市第三人民醫院盧洪洲教授牽頭承擔的「新發突發與重大傳染病防控」國家科技重大專項「功能性儲存庫內潛伏病毒再激活的功能性治癒臨床研究」項目啟動會暨實施方案論證會在深圳順利召開。 項目直指全球醫學界長期面臨的重大挑戰——愛滋病功能性治癒，其核心攻關方向是對體內潛伏病毒儲存庫進行精準評估、安全再激活並實現靶向清除，以期建立一套具備臨床可及性與推廣價值的愛滋病功能性治癒新範式。項目匯聚了領域內頂尖力量，構築了從基礎研究、技術突破到臨床轉化、產業落地的完整創新鏈條。研究團隊聯合深圳市第三人民醫院、中山大學、香港大學深圳醫院、南方科技大學、上海市公共衛生臨床中心等國內高水平科研與醫療機構，並攜手行業龍頭企業，形成了產學研醫深度融合的協同攻關體系  

恭賀醫克生物控股(香港) 有限公司榮獲首屆「粤港澳大灣區創業大賽」 醫藥健康與生物製造賽道 - 特等獎  

醫克生物於香港啟動 治療性的愛滋病疫苗臨床I期試驗   醫克生物科技集團 (「醫克生物」) 今天欣然宣布，治療性的愛滋病核酸疫苗艾絲為克（「ICVAX」）臨床I期試驗正式啟動。該臨床研究由醫克生物與香港中文大學醫學院、香港大學愛滋病研究所和粵港澳大灣區國際臨床試驗中心合作開展。   作為醫克生物專利「PD-1增強型核酸疫苗技術平台」下的主要候選疫苗，ICVAX旨在實現持續的、免疫介導的HIV-1病毒控制，而無需長期使用抗逆轉錄病毒療法（又稱「雞尾酒療法」）抑制HIV，從而達致功能性治癒的最終目標。繼在深圳成功進行ICVAX首次人體I期臨床試驗顯示出卓越的安全性和免疫原性特點後，這項臨床研究將探討ICVAX在香港感染愛滋病毒的志願者中的安全性和免疫原性，並採用三種不同的給藥系統用於ICVAX的藥物遞送。這種對比方法將提供關鍵數據, 以確定ICVAX的最佳遞送方法，從而有望找出對愛滋病毒感染者最有效、對患者友好、和最可擴展的最佳方案。   該臨床研究將在威爾斯親王醫院進行，由香港中文大學醫學院內科及藥物治療學系感染及傳染病組主任雷頌恩醫生擔任首席研究員。這是一項隨機臨床研究，旨在評估ICVAX在22名感染HIV的志願者中的免疫原性和安全性使用三種不同遞送系統：Teresa-EPT-I電穿孔（「EP」）遞藥器械；WHO 預審資格認證的PharmaJet 的Tropis 無針注射系統為遞藥器械；以及佳揚生物的TriGrid EP遞藥器械。   該研究已獲得香港特區政府創新科技署轄下的創新及科技基金的公營機構試用計劃（「PSTS」）的420萬港元資助（項目參考編號：UTT/002/23GM）。香港大學愛滋病研究所所長兼醫克生物首席科學顧問陳志偉教授擔任該資助基金的項目負責人。該研究亦同時獲得教育局轄下的大學教育資助委員會的研究資助局的主題研究計劃（「TRS」）的部分資助（項目參考編號：T11-702/24-N）。 雷頌恩醫生表示: 「這項I期臨床研究是一個重要的里程碑，這是ICVAX首次在香港志願者中進行評估，並採用了多種創新的藥物遞送技術。通過測試這些遞藥器械，我們旨在優化這種具潛力的愛滋病治療性核酸候選疫苗的安全性，免疫原性和患者舒適性。」   陳志偉教授指出：「ICVAX是基於在香港大學發明和研發的創新性PD-1增強型酸疫苗技術。這項研究將有助於優化ICVAX的藥物遞送，為更廣泛的國際性布局做好準備。」   醫克生物行政總裁金俠博士道: 「啟動這項臨床研究是醫克生物的一個重要里程碑。通過ICVAX在香港的首次測試、並比較三種創新的遞藥器械，該研究不僅加深了我們對核酸藥物藥效的理解，而且全力支持ICVAX和其他核酸藥物的全球商業化。醫克生物將繼續致力於在傳染病和癌症領域引領免疫療法的創新。」     醫克生物於香港啟動 治療性的愛滋病疫苗臨床I期試驗    

第十四屆中國創新創業比賽前海港澳台賽收官     第十四屆中國創新創業比賽前海港澳台賽收官   初冬的前海，創新創業熱度依舊居高不下。 11月26日，第十四屆中國創新創業大賽前海港澳台大賽決賽（下稱「大賽」）暨頒獎典禮在深圳前海深港青年夢工場舉行。經過4個月的激烈角逐，5個項目從900餘個項目中脫穎而出、斬獲金獎，為大賽畫下圓滿句點。   作為中國創新創業大賽體系內唯一連通港澳台地區的專項賽事，本屆大賽不僅升格為國家級港澳台專項，還首次設立人工智慧與具身智慧、生命健康、新材料新能源與節能環保、文化創意與體育科技、金融科技及其他五大產業賽道，參賽規模與品質實現雙突破。   項目數量方面，比賽共吸引906個項目報名，較去年增加近50%。其中，人工智慧與具身智慧（259個參賽項目）、生命健康（212個參賽項目）兩大賽道成為科創熱點聚集區。   此次參賽項目中的博士領軍項目達233個，佔近1/4。既湧現出上海固存芯控的國產固態儲存主控晶片、發表於《Science Robotics》的Hopcopter跳躍機器人等攻克「卡脖子」技術的硬核成果，也涵蓋耶魯大學光學博士主導的新型發光材料研發、哈佛大學博士後創立的RNA剪接編輯技術等頂尖人才領銜的創新項目。   「之前很少見到博士級的科學家投身創業！這不僅反映出前海日漸濃厚的創新創業氛圍，更展現出其作為粵港澳大灣區門戶樞紐八面來風的氣勢與鮮明的國際範兒。」融創投資創始合夥人趙俊峰說。   經過激烈角逐，深圳市生境科技有限公司（人工智慧與具身智慧賽道）、醫克生物控股（香港）有限公司（生命健康賽道）、大乙半導體材料（深圳）有限公司（新材料新能源與節能環保賽道）、深圳風脊者科技有限公司（文化創意與體育科技賽道）、艾視光電賽有限公司（金融及其他賽道）分別斬獲五大賽道獎。  

Immuno Cure wins Grand Prize at the National GBA Entrepreneurship Competition   Immuno Cure BioTech (“Immuno Cure”) is delighted to announce victory at the National Final of the 1st GBA Entrepreneurship Competition (the "Competition") on 27 September 2025 in Foshan, Guangdong. Immuno Cure stood out among 7,146 entries nationwide with its first-in-class, therapeutic DNA Vaccine for HIV/AIDS, ICVAX, winning the Grand Prize as the Champion in the Biomedical and Bio-manufacturing Track of the Competition. Further highlighting the event, Immuno Cure attracted an expression of interest for RMB 60 million investment from a major mainland investment fund. Such recognition had demonstrated Immuno Cure’s huge potentials in the field of innovative biomedicine.   Jointly hosted by the Ministry of Human Resources and Social Security, the Hong Kong and Macao Work Office, the State Council’s Hong Kong and Macao Affairs Office, and the Guangdong Provincial People's Government, the Competition, started in May this year, has brought together high-quality technological and innovative companies nationwide. Over 30% of the contestants in the finals were from Hong Kong and Macao. Dr. Xia JIN, Co-founder and CEO of Immuno Cure fully demonstrating the project’s technological breakthrough and market potential throughout several rounds of the Competition.    粵港澳大灣區創業大賽 - 特等奖 (2025/9)  Nation al GBA Entrepreneurship Competition 2025-Grand Prize   Immuno Cure’s therapeutic DNA Vaccine for HIV/AIDS (“ICVAX”) is developed based on the patented technology invented by Professor Zhiwei CHEN and his team at the AIDS Institute of the University of Hong Kong (“HKU”). This technology can significantly enhance cellular immunity and immune response in human, with remarkable effects in controlling viral infections and suppressing tumor growth. Based on the patented technology that was exclusively and globally licensed-in from the HKU, Immuno Cure has developed its “PD-1-Enhanced Vaccine Technology Platform” for the treatment of infectious diseases and a wide range of cancers. Currently, ICVAX has completed the Phase I clinical trial with promising safety and immunogenicity profiles, and will enter Phase II clinical trials shortly. Upon meeting of the endpoints of the Phase II trial, Immuno Cure plans to submit an application for Breakthrough Therapy Designation for ICVAX, aiming for an advanced commercialization in 2028, and bringing a novel solution for global HIV treatment.

Pandemic Vaccine Preparedness Symposium 大流行疫苗防範研討會

會議簡介：   為了更好地推動愛滋病領域的交流與合作，進一步促進新型艾滋疫苗和愛滋病功能性治癒的研究，由清華大學基礎醫學院、清華大學萬科公共衛生與健康學院和中國性病愛滋病防治協會共同主辦的「愛滋病大挑戰」學術交流會，定於2025年12月13日在清華大學召開。   本次會議將針對當前國內外愛滋病研究領域的熱點和難點，邀請臨床和科研一流專家，在愛滋病的新型治療藥物、功能性治癒和新型疫苗研發等方面共同交流與探討，分享新技術、新理論、新療法和新成果，並充分開展合作，期望未來在新型愛滋病治療藥物、疫苗和愛滋病功能性治癒等研究方面取得重大突破。         https://mp.weixin.qq.com/s/b8DjWyvHo5eRsudSsiEcSQ

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to reduce the severity of infections such as bird flu, and cure HIV and other chronic conditions. Synthetic antibodies could also make vaccines for diseases such as COVID-19 more effective.     "Monoclonal antibodies are also widely used in antiviral therapies to treat severe infections caused by Ebola, respiratory syncytial virus (RSV) and the COVID-19 virus SARS-CoV-2, says Runhong Zhou, who studies immune responses at Hong Kong University."         https://www-nature-com.eproxy.lib.hku.hk/articles/d41586-025-03540-4

Keynote Speakers:  Professor Sharon Lewin, Doherty Institute Professor David Ho, Columbia University Professor Linfa Wang, Duke-NUS Medical School Professor Zhiwei Chen, HKUMed Professor Nanshan Zhong, Guangzhou Laboratory Professor Linqi Zhang, Tsinghua University

Join HKU Innovation Week 2025   October 14, 2025 Loke Yell Hall, HKU

在全球愛滋病研究逐漸降溫、疫苗研發多年未果的背景下，一家總部位於香港科學園的初創公司——醫克生物（Immuno Cure）卻悄然登上國際舞台，成為首批完成針對愛滋病治療性核酸疫苗臨牀試驗的科研機構之一。從港大實驗室走到臨牀試驗，踏出改寫治療規則的第一步。 今期《封面故事》專訪醫克生物聯合創始人陳志偉教授及戈壁創投管理合夥人唐啟波（Chibo Tang）兩人分別從科學家與投資人的視角，講述這場長達十年的深科技轉化故事。從一項實驗室專利，如何走到臨牀試驗開始，梳理香港科研轉化制度的斷點與契機，揭示當資本遇上具備平台潛力的科研技術時，如何共同創造出一場足以改寫治療模式與市場格局的創投實驗。edigest.hk/商業/創投實驗-封面故事-醫克生物-愛滋病-1902149/

An Endowed Professorship is one of the most significant awards bestowed upon eminent academics within the University in support of their academic and research activities.Prof Chen is awarded Suen Chi-Sun Professorship in Clinical Science at October 2024.     More Information

Clarivate has named a record-breaking 32 researchers from HKUMed as ‘Highly Cited Researchers 2024’ today (19 November 2024). This accolade further affirms our steadfast commitment to innovation and excellence in medical and health research. Hong Kong has proudly secured its position as the 8th highest-ranking region globally, with 134 researchers recognised as Highly Cited Researchers (HCRs). Among them, 55 are HKU scholars, and HKUMed accounts for 58.2% of the HKU total (32 out of 55) and 23.9% of the Hong Kong total (32 out of 134), respectively. This research accolades highlighted HKUMed’s significant role in contributing to the city’s ascent into the global Top 10 and is yet another example of our global academic excellence and research prowess. Record number of HKUMed scientists named Highly Cited Researchers 2024 by Clarivate In economics, GDP per capita is an important indicator of economic prosperity. In the context of research impact, the number of HCRs per capita provides a likewise metric for global scientific and technological progress. In this regard, Hong Kong leads the world with the highest number of HCRs per capita, boasting an impressive 18.4 HCRs per one million population. As a major driver to this success, HKUMed ranked 8th globally, surpassing major countries / regions like Germany and France.[i] This underscores the extraordinary concentration of top researchers and eminent scientists among us in the Medical Faculty. I extend my heartfelt commendation to our scholars and researchers for their unwavering dedication and hard work! At the same time, members may have observed a proliferation of university rankings, with each ranking system emphasising different criteria and catering to diverse perspectives and purposes. For instance, the Global Ranking of Academic Subjects (GRAS) released most recently by Shanghai Ranking evaluates universities worldwide by subjects using a unique methodology. The six subjects applicable to HKUMed included Human Biological Sciences, Clinical Medicine, Public Health, Nursing, Pharmacy & Pharmaceutical Sciences and Medical Technology. Interestingly, HKUMed ranks 15th in the Public Health subject and >100 in Clinical Medicine. This stands in stark contrast with some university ranking systems which use more comprehensive metrics such as Times Higher Education (Clinical & Health) and QS World University Rankings (Life Sciences & Medicine), which respectively ranked HKUMed as 19th and 31st in the world in 2024 and consistently amongst the top medical schools worldwide years after years. It is therefore crucial to interpret such multi-faceted ranking results with a discerning eye. I will provide more details on the relevant rankings at the upcoming Dean & Heads Advisory Committee and Faculty Board meetings. HKUMed’s recent achievements, including our leadership roles in The Hong Kong Jockey Club Global Health Institute and the Greater Bay Area International Clinical Trial Institute, as well as our membership in the World Health Summit Academic Alliance, have strategically positioned us to tackle new and emerging challenges. These successes not only advance Hong Kong’s health agenda but also allow us to make a substantial impact on global health.

Statistics at a glance: 2024 Highly Cited Researchers – Hong Kong: 134; HKU: 55; HKUMed: 32. 2024 THE World University Rankings – 19th worldwide in ‘Clinical and Health’. 2024 QS World University Rankings - 31st globally in ‘Life Sciences and Medicine’.     Clarivate has named a record-breaking 32 researchers from HKUMed as ‘Highly Cited Researchers 2024’ today (19 November 2024). This accolade further affirms our steadfast commitment to innovation and excellence in medical and health research.   Hong Kong has proudly secured its position as the 8th highest-ranking region globally, with 134 researchers recognised as Highly Cited Researchers (HCRs). Among them, 55 are HKU scholars, and HKUMed accounts for 58.2% of the HKU total (32 out of 55) and 23.9% of the Hong Kong total (32 out of 134), respectively. This research accolades highlighted HKUMed’s significant role in contributing to the city’s ascent into the global Top 10 and is yet another example of our global academic excellence and research prowess.     In economics, GDP per capita is an important indicator of economic prosperity. In the context of research impact, the number of HCRs per capita provides a likewise metric for global scientific and technological progress. In this regard, Hong Kong leads the world with the highest number of HCRs per capita, boasting an impressive 18.4 HCRs per one million population. As a major driver to this success, HKUMed ranked 8th globally, surpassing major countries / regions like Germany and France.[i] This underscores the extraordinary concentration of top researchers and eminent scientists among us in the Medical Faculty. I extend my heartfelt commendation to our scholars and researchers for their unwavering dedication and hard work!

專訪｜艾沐茵結合傳統治療　有望成對抗愛滋病有效療法

  新聞連結   科睿唯安（Clarivate） 最新公佈「2023年度最廣獲徵引研究人員」，香港大學（港大）有55學者人次（即計入在多於一個學術領域獲獎的學者）入選，在全球眾院校和科研機構中高踞第13位。 港大今年有51位（數目經Clarivate修訂）傑出學者晉身「2023年度最廣獲徵引研究人員」，創歷年新高。科睿唯安的分析指，由於港大2023年在全球學術同儕中的排名顯著上升，讓香港因而躋身十大地區和國家排名之列。 根據科睿唯安分析，全球有來自67個國家和地區的6,849名學者獲「2023年度最廣獲徵引研究人員」。計入在多於一個學術領域獲獎的學者，今年獲獎人次達7,125，其中3,793位屬於專門的學術範疇，3,332位於跨領域研究發揮影響力。他們的學術著作獲國際間同儕學者廣泛徵引，在學術界中極具影響力。 今年港大的入選學者數目持續增加，人數繼續是香港院校中最多。獲選錄的都是學術表現卓越的世界頂級學者，他們的多份學術著作，2012至2022年間在其學術範疇得以晉身全球被引用最多首1%的學術文章，是所屬研究領域内極具影響力的人物。 「2023年度最廣獲徵引研究人員」名錄中的51位港大學者包括（按英文姓氏排列）: 化學戴宏杰教授理學院化學系講座教授 Fraser Stoddart理學院化學系講座教授 化學，材料科學譚超良博士工程學院電機電子工程系助理教授 計算機科學黃凱斌教授工程學院電機電子工程系教授及副系主任 跨領域施綺芸教授李嘉誠醫學院公共衞生學院名譽教授 陳雲玫博士李嘉誠醫學院臨床醫學學院微生物學系專職研究員陳鴻霖教授李嘉誠醫學院臨床醫學學院微生物學系教授 陳志偉教授李嘉誠醫學院臨床醫學學院微生物學系免疫學和免疫療法學講座教授、香港大學愛滋病研究所所長鄭智聰教授李嘉誠醫學院臨床醫學學院微生物學系名譽臨床教授 郭健恒博士李嘉誠醫學院臨床醫學學院微生物學系副教授黎青龍教授李嘉誠醫學院榮休教授林讚育教授李嘉誠醫學院公共衞生學院副教授 劉浩然博士李嘉誠醫學院公共衞生學院名譽助理教授李玉國教授工程學院機械工程系建築環境講座教授梁順林教授社會科學學院地理系講座教授 梁詩敏博士李嘉誠醫學院公共衞生學院流行病和生物統計學助理教授麥德華教授李嘉誠醫學院臨床醫學學院病理學系名譽教授裴偉士教授李嘉誠醫學院公共衞生學院病毒學講座教授、譚華正基金教授（醫療科學）譚永輝醫生李嘉誠醫學院臨床醫學學院內教學系名譽臨床助理教授 湯初陽教授工程學院土木工程系講座教授 汪涵教授工程學院電機電子工程系教授王中銳博士工程學院電機電子工程系助理教授 胡子祺教授李嘉誠醫學院公共衞生學院流行病和生物統計學教授吳蓬博士李嘉誠醫學院公共衞生學院流行病和生物統計學助理教授嚴慧玲博士李嘉誠醫學院公共衞生學院公共衞生實驗室科學副教授 楊偉國教授李嘉誠醫學院臨床醫學學院矯形及創傷外科學系教授 尹曉波教授港大協理副校長、工程學院及理學院教授葉植恩博士李嘉誠醫學院臨床醫學學院微生物學系名譽助理教授張錦霞博士李嘉誠醫學院臨床醫學學院微生物學系科學主任 張曉玲教授建築學院房地產及建設系教授 周婕博士李嘉誠醫學院臨床醫學學院微生物學系助理教授 周宇宇教授社會科學學院地理系教授 環境及生態；地球科學劉竹教授社會科學學院地理系教授 地球科學宮鵬教授港大副校長（學術發展）、社會科學學院及理學院講座教授趙國春教授理學院地球科學系講座教授 免疫學蔡建飄先生李嘉誠醫學院臨床醫學學院微生物學系專職研究員孔繁毅教授李嘉誠醫學院臨床醫學學院內科學系傳染病科講座教授、列汝儉列黃瑞容基金教授（健康科學教育學), 及傳染病科主任 梁卓偉教授李嘉誠醫學院公共衞生學院名譽臨床教授 免疫學，微生物學陳福和醫生李嘉誠醫學院臨床醫學學院微生物學系臨床副教授陳國雄博士李嘉誠醫學院臨床醫學學院微生物學系名譽助理教授 朱軒博士李嘉誠醫學院臨床醫學學院微生物學系助理教授杜啟泓教授李嘉誠醫學院臨床醫學學院微生物學系系主任兼臨床教授袁國勇教授李嘉誠醫學院臨床醫學學院微生物學系傳染病學講座教授、霍英東基金教授（傳染病學） 免疫學，社會科學高本恩教授李嘉誠醫學院公共衞生學院流行病和生物統計學分部主任、流行病學講座教授 材料科學李連忠教授工程學院機械工程系未來電子講座教授 微生物學潘烈文教授李嘉誠醫學院公共衞生學院公共衞生實驗室科學分部主任、公共衞生病毒學講座教授 袁碩峰博士李嘉誠醫學院臨床醫學學院微生物學系助理教授張彤教授工程學院土木工程系環境工程講座教授 物理學姚望教授理學院物理學系講座教授張霜教授理學院及物理學系系主任(暫任)、講座教授、工程學院電機電子工程系講座教授張翔教授港大校長、工程學院及理學院講座教授傳媒查詢香港大學傳訊及公共事務處尹慧筠  電話：2859 2600 ｜ 電郵：melwkwan@hku.hk吳婷 電話：3910 3612｜ 電郵： ngjaymee@hku.hk蔡建豪 電話：2859 2607｜電郵： khkchoi@hku.hk

新聞連結